• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis.

作者信息

Ocio Enrique M, Perrot Aurore, Moreau Philippe, Mateos Maria-Victoria, Bringhen Sara, Martínez-López Joaquín, Karlin Lionel, Wang Song-Yau, Oprea Corina, Li Yi, Kodas Ercem, San-Miguel Jesus

机构信息

Servicio de Hematología y Hemoterapia, Hospital Universitario Marqués de Valdecilla University Hospital (IDIVAL) Universidad de Cantabria Santander Spain.

Service d'Hématologie, CHU de Toulouse, IUCT-O Université de Toulouse Toulouse France.

出版信息

Hemasphere. 2024 Nov 5;8(11):e70041. doi: 10.1002/hem3.70041. eCollection 2024 Nov.

DOI:10.1002/hem3.70041
PMID:39507853
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11538320/
Abstract
摘要

相似文献

1
30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis.新诊断多发性骨髓瘤患者中isatuximab的30分钟输注：1b期研究分析结果
Hemasphere. 2024 Nov 5;8(11):e70041. doi: 10.1002/hem3.70041. eCollection 2024 Nov.
2
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
3
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.来那度胺、硼替佐米和地塞米松联合伊沙妥昔单抗用于新诊断、适合移植的多发性骨髓瘤患者的诱导治疗（GMMG-HD7）：一项开放标签、多中心、随机、主动对照、3 期临床试验的第 1 部分。
Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0.
4
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤伊沙妥昔单抗短程固定剂量输注联合治疗的 1b 期研究的最终结果。
Leukemia. 2021 Dec;35(12):3526-3533. doi: 10.1038/s41375-021-01262-w. Epub 2021 May 28.
5
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma.抗CD38抗体isatuximab给药便利性的最新进展：皮下给药及在多发性骨髓瘤患者中的快速静脉输注
Clin Lymphoma Myeloma Leuk. 2024 Jun;24(6):358-363. doi: 10.1016/j.clml.2024.02.004. Epub 2024 Feb 12.
6
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.伊沙佐米、卡非佐米、来那度胺和地塞米松治疗新诊断、适合移植的多发性骨髓瘤患者（SKylaRk）：一项单臂、2 期临床试验。
Lancet Haematol. 2024 Jun;11(6):e415-e424. doi: 10.1016/S2352-3026(24)00070-X. Epub 2024 Apr 24.
7
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.isatuximab联合来那度胺及地塞米松治疗复发/难治性多发性骨髓瘤的1b期研究
Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.
8
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.来那度胺、硼替佐米和地塞米松联合依鲁替尼或伊沙妥昔单抗治疗初诊多发性骨髓瘤患者后的干细胞采集：来自 GMMG-HD6 和 -HD7 试验的单中心经验。
BMC Cancer. 2023 Nov 21;23(1):1132. doi: 10.1186/s12885-023-11507-9.
9
Isatuximab for the treatment of relapsed/refractory multiple myeloma.依沙佐米单抗治疗复发/难治性多发性骨髓瘤。
Expert Opin Biol Ther. 2020 Dec;20(12):1395-1404. doi: 10.1080/14712598.2021.1841747.
10
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.一项关于伊沙妥昔单抗联合泊马度胺/地塞米松治疗复发/难治性多发性骨髓瘤的 1b 期研究。
Blood. 2019 Jul 11;134(2):123-133. doi: 10.1182/blood-2019-02-895193. Epub 2019 Mar 12.

引用本文的文献

1
The CD39/CD73/Adenosine and NAD/CD38/CD203a/CD73 Axis in Cutaneous T-Cell Lymphomas.皮肤T细胞淋巴瘤中的CD39/CD73/腺苷与NAD/CD38/CD203a/CD73轴
Cells. 2025 Feb 19;14(4):309. doi: 10.3390/cells14040309.

本文引用的文献

1
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.伊沙佐米、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3.
2
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.伊沙佐米、来那度胺、地塞米松和硼替佐米治疗不适合移植的多发性骨髓瘤：随机 3 期 BENEFIT 试验。
Nat Med. 2024 Aug;30(8):2235-2241. doi: 10.1038/s41591-024-03050-2. Epub 2024 Jun 3.
3
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.来那度胺、硼替佐米和地塞米松联合伊沙妥昔单抗治疗不适合/无立即进行自体造血干细胞移植意向的新诊断多发性骨髓瘤患者的疗效和安全性。
Leukemia. 2023 Jul;37(7):1521-1529. doi: 10.1038/s41375-023-01936-7. Epub 2023 Jun 14.
4
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.一项评估达雷妥尤单抗在复发/难治性多发性骨髓瘤患者中加速输注率的 II 期、开放标签研究。
Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):484-490. doi: 10.1016/j.clml.2023.03.006. Epub 2023 Mar 24.
5
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy.早期多发性骨髓瘤免疫治疗策略的临床证据：后续治疗决策中的当前挑战。
Blood Cancer J. 2023 Mar 22;13(1):41. doi: 10.1038/s41408-023-00804-y.
6
Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.isatuximab联合硼替佐米、环磷酰胺和地塞米松用于新诊断的、不适合移植的多发性骨髓瘤患者的1b期研究
Hemasphere. 2023 Jan 31;7(2):e829. doi: 10.1097/HS9.0000000000000829. eCollection 2023 Feb.
7
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.来那度胺、硼替佐米和地塞米松联合伊沙妥昔单抗用于新诊断、适合移植的多发性骨髓瘤患者的诱导治疗（GMMG-HD7）：一项开放标签、多中心、随机、主动对照、3 期临床试验的第 1 部分。
Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0.
8
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.抗 CD38 抗体治疗复发/难治性多发性骨髓瘤患者：不同的作用机制和最近的临床试验结果。
Ann Hematol. 2022 Oct;101(10):2123-2137. doi: 10.1007/s00277-022-04917-5. Epub 2022 Aug 9.
9
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.达雷妥尤单抗快速输注的安全性：对134例多发性骨髓瘤患者的回顾性、多中心、真实世界分析
Front Oncol. 2022 Mar 14;12:851864. doi: 10.3389/fonc.2022.851864. eCollection 2022.
10
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.多发性骨髓瘤：欧洲血液学协会-欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3.